


Ask a doctor about a prescription for BUPRENORPHINE TEVA 70 micrograms/hour transdermal patch
Package Leaflet: Information for the User
Buprenorphine Teva 70 micrograms/hour transdermal patch EFG
Buprenorphine
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the pack
The active substance of Buprenorphine Teva is buprenorphine.
Buprenorphine Teva is an analgesic (a medicine for pain relief) indicated for the relief of moderate to severe cancer pain and severe pain that does not respond to other types of analgesics. Buprenorphine Teva acts through the skin. When the transdermal patch is applied to the skin, the active ingredient buprenorphine passes through the skin into the blood. Buprenorphine is an opioid (a strong pain reliever) that reduces pain by acting on the central nervous system (in specific nerve cells in the spinal cord and brain). The effect of the transdermal patch lasts up to a maximum of four days. Buprenorphine Teva is not suitable for the treatment of acute (short-term) pain.
Do not use Buprenorphine Teva
Buprenorphine Teva should not be used to treat withdrawal syndrome in drug addicts.
Warnings and precautions
Consult your doctor or pharmacist before starting to use Buprenorphine Teva
The use of these medicines together with Buprenorphine Teva may cause serotonin syndrome, a potentially life-threatening disease (see “Other medicines and Buprenorphine Teva”),
Also, note the following precautions:
Tolerance, dependence, and addiction
This medicine contains buprenorphine, an opioid substance. Repeated use of opioids can reduce the effectiveness of the medicine (your body gets used to the medicine, this is what is known as tolerance). Repeated use of Buprenorphine Teva can also cause dependence, abuse, and addiction, which can lead to a potentially life-threatening overdose. The risk of side effects may increase with a higher dose and longer duration of use. Dependence or addiction can make you feel like you no longer have control over the amount of medicine you need to take or how often you need to take it.
The risk of becoming dependent or addicted varies from person to person. You may have a higher risk of becoming dependent or addicted to Buprenorphine Teva if:
If you notice any of the following signs while taking Buprenorphine Teva, it could be a sign that you have become dependent or addicted:
If you notice any of these signs, talk to your doctor to address the most appropriate treatment strategy in your case, including when it is appropriate to stop taking it and how to do so safely (see section 3 “If you stop treatment with Buprenorphine Teva”).
Children and adolescents
Buprenorphine Teva should not be used in persons under 18 years of age, as there is no experience with its use in this age group to date.
Other medicines and Buprenorphine Teva
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines.
The concomitant use of Buprenorphine Teva and sedative medicines such as benzodiazepines or related medicines increases the risk of drowsiness, breathing difficulties (respiratory depression), coma, and can be potentially life-threatening. Due to this, concomitant use should only be considered when other treatment options are not possible.
However, if your doctor prescribes Buprenorphine Teva together with sedative medicines, your doctor should limit the dose and duration of concomitant treatment.
Tell your doctor about all sedative medicines you are taking and closely follow the dosage recommendation. It may be useful to inform friends or family members so they are aware of the signs and symptoms indicated above. Contact your doctor when you experience such symptoms.
The concomitant use of Buprenorphine Teva and gabapentinoids such as gabapentin or pregabalin used to treat epilepsy or pain due to nerve problems (neuropathic pain) may cause breathing difficulties (respiratory depression), low blood pressure, deep drowsiness, coma, and can be potentially life-threatening.
Using Buprenorphine Teva with food, drinks, and alcohol
Do not drink alcohol while using Buprenorphine Teva. Alcohol may intensify certain side effects of the transdermal patch and may make you feel unwell. If you drink grapefruit juice, it may intensify the effects of Buprenorphine Teva.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.
There is no sufficient experience with the use of Buprenorphine Teva in pregnant women to date. Therefore, do not use Buprenorphine Teva during pregnancy.
Buprenorphine, the active ingredient in the transdermal patch, inhibits milk production and passes into breast milk. Therefore, do not use Buprenorphine Teva during breastfeeding.
Driving and using machines
Buprenorphine Teva may make you feel dizzy, drowsy, or have double or blurred vision, and may affect your reflexes so that you do not react adequately or quickly enough in case of sudden or unexpected situations. This applies especially:
If you are affected, you should not drive or operate machinery while using Buprenorphine Teva. This also applies at the end of treatment with Buprenorphine Teva. Do not drive or operate machinery for at least 24 hours after removal of the patch.
In case of doubt, consult your doctor or pharmacist.
Follow your doctor's instructions for administering this medication exactly. If in doubt, consult your doctor or pharmacist again.
Before starting treatment and periodically during it, your doctor will discuss with you what you can expect from using this medication, when and for how long you should take it, when to contact your doctor, and when you should stop taking it (see also "If you stop treatment with Buprenorphine Teva").
This medication is available in three doses: Buprenorphine Teva 35 micrograms/hour transdermal patch EFG, Buprenorphine Teva 52.5 micrograms/hour transdermal patch EFG, and Buprenorphine Teva 70 micrograms/hour transdermal patch EFG.
Your doctor has chosen this buprenorphine patch as the most suitable for you. During treatment, your doctor may change the transdermal patch you use to one with a lower or higher dose if necessary.
The recommended dose is:
Adults
Follow these instructions unless your doctor has given you different instructions. Apply the buprenorphine patch (as detailed below) and change it after four days, at most. To facilitate use, you can change the patch 2 times a week on fixed days, e.g., "always on Mondays in the morning and Thursdays in the afternoon". To help you remember when to change the transdermal patch, note it in the carton calendar. If your doctor has instructed you to take other painkillers in addition to the transdermal patch, follow your doctor's instructions strictly; otherwise, you will not fully benefit from the buprenorphine treatment.
Children and adolescents
This medication should not be used in people under 18 years of age because there is no experience in this age group to date.
Elderly patients
No dose adjustment is required in elderly patients.
Patients with renal impairment / patients on dialysis
In patients with renal impairment and patients on dialysis, no dose adjustment is needed.
Patients with hepatic impairment
In patients with hepatic impairment, the intensity and duration of the action of buprenorphine may be affected. If you belong to this group of patients, your doctor will monitor you with greater care.
Method of administration
Before applying a transdermal patch
| Chest |
|
|
Back |
|
|
Applying the transdermal patch:
Step 1: Each transdermal patch is sealed in an envelope. Just before use, cut the envelope along the sealed edge with scissors. Be careful not to damage the transdermal patches. Take the transdermal patch. |
|
Step 2: The adhesive side of the transdermal patch is covered by a transparent protective film. Carefully peel off halfof the film. Try not to touch the adhesive part of the transdermal patch. |
|
Step 3: Stick the transdermal patch to the skin area you have chosen and remove the rest of the film. |
|
Step 4: Press the transdermal patch against your skin with the palm of your hand and count slowly to 30. Make sure the entire transdermal patch is in contact with your skin, especially the edges. |
|
Step 5: Wash your hands after using the transdermal patch. Do not use any cleaning products. | |
While wearing the transdermal patch
You can wear the transdermal patch for up to 4 days. If you have applied the transdermal patch correctly, the risk of it coming off is low. You can shower, bathe, or swim while wearing it. However, do not expose the transdermal patch to extreme heat (e.g., sauna, infrared lamps, electric blankets, or hot water bottles).
In the unlikely event that your transdermal patch falls off before you need to change it, do not use the same transdermal patch again. Apply a new one immediately (see "Changing the transdermal patch" below).
Changing the transdermal patch
Duration of treatment
Your doctor will indicate the duration of your treatment with this medication. Do not stop treatment with buprenorphine on your own, as the pain may return and you may feel unwell (see also "If you stop treatment with Buprenorphine Teva").
If you think the effect of this medication is too strong or too weak, tell your doctor or pharmacist.
If you use more Buprenorphine Teva than you should
If this happens, there may be signs of a buprenorphine overdose. An overdose can intensify the adverse effects of buprenorphine, such as drowsiness, nausea, and vomiting. You may have pinpoint pupils, and your breathing may become slow and weak. You could also suffer a cardiovascular collapse.
As soon as you realize you have used more transdermal patches than you should, remove the excess transdermal patches and consult your doctor or pharmacist immediately.
In case of overdose or accidental ingestion, consult the Toxicology Information Service, phone 91 562 04 20, indicating the medication and the amount used.
If you forget to use Buprenorphine Teva
If you forget an application, apply a new transdermal patch as soon as you remember. This will change your routine, e.g., if you normally apply your transdermal patch on Mondays and Thursdays, but you forget and do not apply the new transdermal patch until Wednesday, from then on you will need to change your transdermal patches on Wednesdays and Saturdays. Note the new pair of days in the carton calendar. If you change the transdermal patch too late, the pain may return. In this case, consult your doctor.
Never apply more than one transdermal patch to make up for the one you forgot!
If you stop treatment with Buprenorphine Teva
If you stop or finish treatment with this medication too early, the pain will return. If you want to stop treatment due to unpleasant side effects, consult your doctor. Your doctor will tell you what you can do and if you can be treated with other medications.
Some people may experience withdrawal effects after using powerful painkillers for a long time and stopping them. The risk of having these effects after stopping the application of buprenorphine patches is very low. However, if you feel agitated, anxious, nervous, or trembly, if you are hyperactive, have difficulty sleeping, or digestive problems, consult your doctor.
If you have any other questions about using this medication, ask your doctor or pharmacist.
Like all medications, this medication can cause side effects, although not everyone will experience them.
If you experience swelling of the hands, feet, knees, face, lips, mouth, or throat, which can cause difficulty swallowing or breathing, hives, fainting, yellowing of the skin and eyes (also called jaundice), remove the transdermal patch and consult your doctor or go to the nearest hospital immediately. These may be symptoms of a rare, severe allergic reaction.
The following side effects have been reported:
Very common(may affect more than 1 in 10 people):
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people):
Rare(may affect up to 1 in 1,000 people):
Very rare(may affect up to 1 in 10,000 people):
Frequency not known(frequency cannot be estimated from available data):
If you notice any of the above side effects, consult your doctor as soon as possible.
In some cases, late local allergic reactions with marked signs of inflammation occur. In these cases, treatment with Buprenorphine Teva should be discontinued after consulting your doctor.
Some people may experience withdrawal symptoms after using powerful painkillers for a long time and stopping them. After treatment with Buprenorphine Teva, the risk of experiencing withdrawal symptoms is low. However, if you feel agitated, anxious, nervous, hyperactive, have sleep disorders, or digestive problems, consult your doctor.
Reporting side effects
If you experience any side effects, consult your doctor or pharmacist, even if they are possible side effects not listed in this leaflet. You can also report them directly through the Spanish Medicines Monitoring System for Human Use: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medication.
Keep this medication out of sight and reach of children.
Do not use this medication after the expiration date stated on the packaging and on the envelope after EXP. The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Keep this medication in a safe and protected place where others cannot access it. It can cause serious harm and be fatal if used accidentally or intentionally by people who have not been prescribed it.
Medications should not be thrown away in drains or trash. Deposit the packaging and medications you no longer need in the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. This will help protect the environment.
Composition of Buprenorphine Teva
The active ingredient is buprenorphine.
Each 50 cm2 transdermal patch contains 40 mg of buprenorphine and releases 70 micrograms of buprenorphine per hour.
The other components are:
Appearance of Buprenorphine Teva and package contents
Beige rectangular patch with rounded edges, printed with "Buprenorphine" and "70 μg / h"
Each transdermal patch is sealed in a child-resistant envelope. The patches are available in packs containing 3, 4, 5, 6, 8, 10, 12, 16, 18, or 20 transdermal patches.
Not all pack sizes may be marketed.
Marketing authorization holder
Teva Pharma S.L.U.
C/ Anabel Segura, 11 Edificio Albatros B, 1ª planta
28108 Alcobendas (Madrid)
Spain
Manufacturer
Labtec GmbH
Heykenaukamp 10, Hamburg
21147 Germany
or
Merckle GmbH
Ludwig-Merckle-Straße 3, Blaubeuren
89143 Germany
or
Teva Operations Poland Sp.z.o.o
ul. Mogilska 80, Krakow
31-546 Poland
This medication is authorized in the Member States under the following names:
Germany: | Buprenoratiopharm 70 Mikrogramm/Stunde Transdermales Pflaster |
Austria: | Buprenorphin ratiopharm 70 Mikrogramm/h transdermales Pflaster |
Belgium: | Buprenorphine Teva 70 microgram/u pleister voor transdermaal gebruik Buprenorphine Teva 70 microgrammes/h dispositif transdermique Buprenorphine Teva 70 Mikrogramm/S transdermales Pflaster |
Spain: | Buprenorfina Teva 70 microgramos/hora parche transdérmico EFG |
Finland: | Buprenorphine ratiopharm 70 mikrog/tunti depotlaastari |
Croatia: | Laribon 70 mikrograma/h transdermalni flaster |
Netherlands: | Buprenorfine Teva 70 microgram/uur pleister voor transdermaal gebruik |
Portugal: | Buprenorfina ratiopharm |
United Kingdom: | Timpron 70 micrograms/h Transdermal patch |
Date of the last revision of this leaflet:October 2024
Detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
You can access detailed and updated information about this medication by scanning the QR code included in the packaging with your smartphone. You can also access this information at the following internet address: https://cima.aemps.es/cima/dochtml/p/80611/P_80611.html
QR+URL
The average price of BUPRENORPHINE TEVA 70 micrograms/hour transdermal patch in November, 2025 is around 43.04 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for BUPRENORPHINE TEVA 70 micrograms/hour transdermal patch – subject to medical assessment and local rules.